Sagimet Biosciences Inc/$SGMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sagimet Biosciences Inc
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Ticker
$SGMT
Sector
Primary listing
Employees
14
Headquarters
Website
SGMT Metrics
BasicAdvanced
$239M
-
-$1.84
3.41
-
Price and volume
Market cap
$239M
Beta
3.41
52-week high
$11.41
52-week low
$1.73
Average daily volume
763K
Financial strength
Current ratio
17.552
Quick ratio
17.305
Total debt to equity
0.117
Profitability
Management effectiveness
Return on assets (TTM)
-25.61%
Return on equity (TTM)
-37.89%
Valuation
Price to book
1.82
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
-4.366
Free cash flow yield (TTM)
-22.91%
Free cash flow per share (TTM)
-1.684
Growth
Earnings per share change (TTM)
61.38%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sagimet Biosciences Inc stock?
Sagimet Biosciences Inc (SGMT) has a market cap of $239M as of August 22, 2025.
What is the P/E ratio for Sagimet Biosciences Inc stock?
The price to earnings (P/E) ratio for Sagimet Biosciences Inc (SGMT) stock is 0 as of August 22, 2025.
Does Sagimet Biosciences Inc stock pay dividends?
No, Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Sagimet Biosciences Inc dividend payment date?
Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sagimet Biosciences Inc?
Sagimet Biosciences Inc (SGMT) has a beta rating of 3.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.